Abstract
The number of individuals afflicted by Alzheimer’s disease (AD) worldwide is rapidly rising and we, as a society, are approaching a critical junction in the development of new therapeutics aimed at slowing or preventing the onset of this devastating neurodegenerative disease. The prevailing theory in the field pinpoints the amyloid β peptide (Aβ) as the causal agent of the disease and thus strategies that target the production, deposition, and clearance of Aβ in the brain continue to be at the forefront of therapeutic interventions. Aβ is produced through a series of proteolytic cleavage events, with β-secretase (BACE1) being the rate-limiting enzymatic activity needed to begin the liberation of the Aβ peptide from the larger amyloid precursor protein (APP). As such, BACE1 itself has become a prime therapeutic target for AD. Still, over ten years after its discovery, only a handful of compounds targeting BACE1 have reached clinical trial, indicating that complex challenges continue to persist. This short review will focus on the cellular and molecular characteristics of BACE1, its role in APP processing and in AD, and its potential as a therapeutic target for AD.
Keywords: Alzheimer’s Disease, amyloid β-Peptide, β-Secretase, BACE1, therapeutics.
Current Enzyme Inhibition
Title:BACE1: Expression, Regulation, and Therapeutic Potential of the Major Alzheimer’s Disease Beta-Secretase
Volume: 9 Issue: 1
Author(s): Christopher J. Holler and Michael P. Murphy
Affiliation:
Keywords: Alzheimer’s Disease, amyloid β-Peptide, β-Secretase, BACE1, therapeutics.
Abstract: The number of individuals afflicted by Alzheimer’s disease (AD) worldwide is rapidly rising and we, as a society, are approaching a critical junction in the development of new therapeutics aimed at slowing or preventing the onset of this devastating neurodegenerative disease. The prevailing theory in the field pinpoints the amyloid β peptide (Aβ) as the causal agent of the disease and thus strategies that target the production, deposition, and clearance of Aβ in the brain continue to be at the forefront of therapeutic interventions. Aβ is produced through a series of proteolytic cleavage events, with β-secretase (BACE1) being the rate-limiting enzymatic activity needed to begin the liberation of the Aβ peptide from the larger amyloid precursor protein (APP). As such, BACE1 itself has become a prime therapeutic target for AD. Still, over ten years after its discovery, only a handful of compounds targeting BACE1 have reached clinical trial, indicating that complex challenges continue to persist. This short review will focus on the cellular and molecular characteristics of BACE1, its role in APP processing and in AD, and its potential as a therapeutic target for AD.
Export Options
About this article
Cite this article as:
J. Holler Christopher and P. Murphy Michael, BACE1: Expression, Regulation, and Therapeutic Potential of the Major Alzheimer’s Disease Beta-Secretase, Current Enzyme Inhibition 2013; 9 (1) . https://dx.doi.org/10.2174/1573408011309010003
DOI https://dx.doi.org/10.2174/1573408011309010003 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Machine Learning and Social Network Analysis Applied to Alzheimer's Disease Biomarkers
Current Topics in Medicinal Chemistry Methods for Identifying Cardiovascular Agents: A Review
Recent Patents on Cardiovascular Drug Discovery HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-κBYY1 Pathway
Current HIV Research The Role of LRRK2 in Neurodegeneration of Parkinson Disease
Current Neuropharmacology Tachykinins and Tachykinin Receptors: Structure and Activity Relationships
Current Medicinal Chemistry Development of FXR, PXR and CAR Agonists and Antagonists for Treatment of Liver Disorders
Current Topics in Medicinal Chemistry Gestational Exposure to Variable Stressors Produces Decrements in Cognitive and Neural Development of Juvenile Male and Female Rats
Current Topics in Medicinal Chemistry Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy Biological and Pharmacological Activities of Iridoids: Recent Developments
Mini-Reviews in Medicinal Chemistry Goal Directed Fluid Therapy
Current Pharmaceutical Design Acute Right Ventricular Failure in the Setting of Acute Pulmonary Embolism or Chronic Pulmonary Hypertension: A Detailed Review of the Pathophysiology, Diagnosis, and Management
Current Cardiology Reviews Antioxidant Activities of Retinoidal Benzimidazole Or Indole Derivatives in In Vitro Model Systems
Current Medicinal Chemistry Hypopituitarism in the Elderly: Multifaceted Clinical and Biochemical Presentation
Current Aging Science Transport of Cryptotanshinone, a Major Active Triterpenoid in Salvia Miltiorrhiza Bunge Widely Used in the Treatment of Stroke and Alzheimers Disease, Across the Blood-Brain Barrier
Current Drug Metabolism The Future of Neuroregenerative Therapy for Parkinson’s Disease
Current Tissue Engineering (Discontinued) Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Neural Mechanism of Exercise: Neurovascular Responses to Exercise
CNS & Neurological Disorders - Drug Targets Novel Peptides: An Alternative Approach for the Treatment of Diabetes Mellitus
Current Drug Therapy Preface [Hot Topic: New Clinical Applications for Naturally Occurring Peptide Toxins (Guest Editors: Robert Jones / Graeme Semple)]
Current Medicinal Chemistry